Doximity Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.3%projected annual EPS growth
Analyst Coverage
18analysts covering
FY Revenue (est.)
$676.3Mnext fiscal year
FY EPS (est.)
$1.36next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Active Prescribers Quarterly800K
Net Revenue Retention (NRR) Rate Annually109.0%
Customers Contributing At Least $500,000 in TTM Subscription Revenue Quarterly125
Watch Items
- Pharmaceutical Digital Marketing Budgets
- AI Suite Monetization and Compute Costs
- CFO Leadership TransitionTrigger: Appointment of a permanent Chief Financial OfficerAction: Evaluate the background and strategic focus of the new CFO once appointed to replace interim CFO Siddharth Sitaram.
Research as of 19 Jun 2026